Ekso Bionics (EKSO) shares nearly doubled on Dec. 30 after Applied Digital (APLD) revealed plans of spinning off its cloud segment into a standalone business. The announcement sparked investor enthusiasm for Ekso Bionics, as that company would merge with the spunoff cloud segment of Applied Digital to create a new company, ChronoScale. More News from Barchart Despite this explosive surge, EKSO stock remains down roughly 40% versus its year-to-date high. www.barchart.com What APLD Announcement Means f ...

Core Viewpoint - Applied Digital Corp. (NASDAQ:APLD) is implementing a new corporate strategy that involves spinning off its cloud computing business, which has positively impacted its stock performance, leading to a 3.16% increase in share price to $24.81 [1][5]. Group 1: Corporate Strategy - Applied Digital Corp. will separate its cloud computing segment by merging it with EKSO Bionics Holdings Inc., creating a new entity focused on AI workloads called ChronoScale [2][3]. - The new company, ChronoScale, will be primarily dedicated to an accelerated compute platform for AI, with Applied Digital retaining a 97% ownership stake [3]. Group 2: Market Context - The transaction is designed to address the growing demand for GPU-accelerated cloud infrastructure, aiming to provide high-performance computing solutions in a capacity-constrained market [4]. - By separating the accelerated compute platform from its data center operations, Applied Digital aims to allow both businesses to scale independently and pursue distinct growth strategies [5].

Core Insights - OS Therapies Inc. (OSTX) is advancing towards bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma, with significant clinical and regulatory milestones achieved in 3Q25 [1][3] - The company reported a 2-year overall survival (OS) rate of 75% for OST-HER2 compared to 40% in historical controls, with 100% 2-year survival among patients who were event-free at 12 months [1][5] - A planned spinoff of OS Animal Health (OSAH) into a standalone public company is expected in 1H26, allowing OSTX shareholders to receive direct equity participation [1][5] Regulatory Developments - The regulatory path is on track with a UK pre-MAA submission in December and FDA Type C filings targeted for January 2026, supported by the Phase 2b trial results [5] - The company is preparing for harmonized U.S. and ex-U.S. filings, with submissions to the UK MHRA and FDA expected around year-end [1][5] Financial Overview - As of the end of the quarter, OS Therapies had approximately $1.9 million in cash and reported a net loss of $6.9 million [5] - Post-quarter, the company secured $7.8 million in warrant proceeds and has an At-The-Market (ATM) facility in place, extending its financial runway into late 2026 [5]

Core Viewpoint - Elliott Management has acquired a significant stake in Barrick Mining, indicating potential major changes for the company, including a possible split into two separate entities focused on different geographic regions [1][2]. Group 1: Stakeholder Actions - Elliott Management is reportedly "encouraged" by the potential breakup of Barrick Mining, which has been a topic of discussion since the departure of CEO Mark Bristow [2]. - The idea of a spinoff and possible asset sales has gained traction among analysts following recent leadership changes [2]. Group 2: Company Structure and Market Response - A split would revert Barrick to its pre-2019 structure, prior to its acquisition of Randgold [3]. - Elliott's stake is substantial enough to position it among Barrick's top 10 shareholders, alongside Capital Research & Management and Vanguard [3]. - Following the news, Barrick's NYSE shares rose by 1.4%, resulting in a market capitalization of $63.7 billion, with the stock gaining nearly 135% year-to-date [4]. Group 3: Industry Context - Elliott Management, managing approximately $76 billion in assets, has a history in the mining sector, having previously invested in Anglo American and Triple Flag Precious Metals [4].

Core Insights - The S&P 500 index will see changes with Solstice Advance Materials and Qnity Electronics joining the index, replacing CarMax and Eastman Chemical respectively [1][3][7] Company Changes - Solstice Advance Materials, using the ticker "SOLS," is a spinoff from Honeywell International, which will remain in the S&P 500 [2] - Qnity Electronics, with the ticker "Q," is a spinoff from DuPont de Nemours, which will also continue to be part of the index [2] Index Adjustments - These changes mark the first updates to the S&P 500 since September, when several companies were replaced [4][7] - CarMax and Eastman Chemical will move to the S&P 600 index, which includes smaller companies [3][4]

Group 1 - Honeywell and DuPont are divesting companies in the near future [1] - Both companies will be included in the S&P 500 index [1]

Company Strategy - Siemens is considering spinning off a significant portion of its majority stake in Siemens Healthineers, a medical equipment unit listed in Frankfurt [1] - The spinoff structure is relatively untested [1]